BRPI0417401A - composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto - Google Patents

composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto

Info

Publication number
BRPI0417401A
BRPI0417401A BRPI0417401-1A BRPI0417401A BRPI0417401A BR PI0417401 A BRPI0417401 A BR PI0417401A BR PI0417401 A BRPI0417401 A BR PI0417401A BR PI0417401 A BRPI0417401 A BR PI0417401A
Authority
BR
Brazil
Prior art keywords
mammal
treating
compound
syndrome
disease
Prior art date
Application number
BRPI0417401-1A
Other languages
English (en)
Inventor
Rafael Ferrito Crespo
Maria Dolores Martin-Or Finger
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0417401A publication Critical patent/BRPI0417401A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA MODULAR UM RECEPTOR ATIVADO POR PROLIFERADOR DE PEROXISSOMO, PARA TRATAR DOENçA OU CONDIçãO, PARA ABAIXAR GLICOSE SANGUìNEA EM UM MAMìFERO, PARA TRATAR DIABETES MELLITUS EM UM MAMìFERO, PARA TRATAR DOENçA CARDIOVASCULAR EM UM MAMìFERO, PARA TRATAR SìNDROME X EM UM MAMìFERO, E, USO DE COMPOSTO A presente invenção refere-se a um composto novo, à sua composição e ao uso de um composto possuindo a fórmula estrutural (I), ou de um sal, solvato, hidrato ou estereoisómeros farmaceuticamente aceitáveis do mesmo, que é útil no tratamento ou na prevenção de distúrbios mediados por um receptor ativado por proliferador de peroxissomo (PPAR) tais como síndrome X, diabetes de tipo II, hiperglicemia, hiperlipidemia, obesidade, coagulopatia, hipertensão, arteriosclerose, e outros distúrbios relacionados com síndrome X e doenças cardiovasculares.
BRPI0417401-1A 2003-12-15 2004-12-08 composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto BRPI0417401A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03380288 2003-12-15
US55063604P 2004-03-05 2004-03-05
PCT/US2004/038232 WO2005061441A1 (en) 2003-12-15 2004-12-08 Selective peroxisome proliferator activated receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0417401A true BRPI0417401A (pt) 2007-05-08

Family

ID=34712592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417401-1A BRPI0417401A (pt) 2003-12-15 2004-12-08 composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto

Country Status (25)

Country Link
US (1) US7321056B2 (pt)
EP (1) EP1697306B1 (pt)
JP (1) JP2007516267A (pt)
KR (1) KR100806004B1 (pt)
CN (1) CN1886364A (pt)
AT (1) ATE368026T1 (pt)
AU (1) AU2004303793A1 (pt)
BR (1) BRPI0417401A (pt)
CA (1) CA2549008A1 (pt)
CY (1) CY1106846T1 (pt)
DE (1) DE602004007825T2 (pt)
DK (1) DK1697306T3 (pt)
EA (1) EA009023B1 (pt)
EC (1) ECSP066639A (pt)
ES (1) ES2289589T3 (pt)
HR (1) HRP20070422T3 (pt)
IL (1) IL175997A0 (pt)
MA (1) MA28399B1 (pt)
MX (1) MXPA06006829A (pt)
NO (1) NO20063261L (pt)
PL (1) PL1697306T3 (pt)
PT (1) PT1697306E (pt)
SI (1) SI1697306T1 (pt)
WO (1) WO2005061441A1 (pt)
ZA (1) ZA200604834B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO2000061582A1 (en) * 1999-04-08 2000-10-19 Sankyo Company, Limited Substituted fused imidazole derivatives
AU2002222552A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002083616A1 (en) * 2001-04-10 2002-10-24 Sankyo Company, Limited α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2005529975A (ja) * 2002-06-19 2005-10-06 イーライ・リリー・アンド・カンパニー アミドリンカーペルオキシソーム増殖因子活性化受容体調節因子

Also Published As

Publication number Publication date
IL175997A0 (en) 2006-10-05
KR20060121192A (ko) 2006-11-28
JP2007516267A (ja) 2007-06-21
US7321056B2 (en) 2008-01-22
HRP20070422T3 (en) 2007-11-30
CA2549008A1 (en) 2005-07-07
CY1106846T1 (el) 2012-05-23
CN1886364A (zh) 2006-12-27
ECSP066639A (es) 2006-10-25
AU2004303793A1 (en) 2005-07-07
ES2289589T3 (es) 2008-02-01
DE602004007825D1 (de) 2007-09-06
ATE368026T1 (de) 2007-08-15
DK1697306T3 (da) 2007-11-12
NO20063261L (no) 2006-09-06
EA200601159A1 (ru) 2006-10-27
MA28399B1 (fr) 2007-01-02
EP1697306A1 (en) 2006-09-06
SI1697306T1 (sl) 2008-02-29
US20070066683A1 (en) 2007-03-22
PL1697306T3 (pl) 2007-11-30
EP1697306B1 (en) 2007-07-25
KR100806004B1 (ko) 2008-02-26
EA009023B1 (ru) 2007-10-26
MXPA06006829A (es) 2006-08-23
DE602004007825T2 (de) 2008-04-17
HK1097406A1 (en) 2007-06-22
ZA200604834B (en) 2007-11-28
PT1697306E (pt) 2007-10-19
WO2005061441A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
PE20110841A1 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
NO20051161L (no) Azulenderivater og salter derav
ATE386715T1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
NO20090591L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
UA100008C2 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит
ATE440091T1 (de) Antidiabetische bicyclische verbindungen
EA201000321A1 (ru) Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
NO20082445L (no) Neuropeptid-2 reseptor-agonister
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
AP2002002634A0 (en) Malonamic Acids And Derivatives Thereof As Thyroid Receptor Ligands.
BR0211414A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
BRPI0407303A (pt) Composição farmacêutica
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
MX2010001352A (es) Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares.
BRPI0417401A (pt) composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto
BR0315683A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
BRPI0417469B8 (pt) bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes
NO20054214L (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
WO2008094860A3 (en) Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
BRPI0606201A2 (pt) composto rigidificado para modulação da atividade de heparanase e composição farmacêutica
UA83265C2 (ru) Селективные модуляторы рецепторов, которые активируются пролифераторами пероксисом
BR0308393A (pt) Aplicação do pegvisomant (somavert) na preparação de uma composição farmacêutica para o tratamento de diabetes melito tipo 1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.